Drug Eluting Stent Market Size (2024 - 2029)

The drug-eluting stent market is anticipated to experience growth over the forecast period, driven by factors such as the rising prevalence of cardiovascular diseases and an increasing demand for minimally invasive surgeries. The market's expansion is supported by the adoption of these stents to prevent the re-narrowing of blood vessels, particularly in patients with peripheral and coronary artery diseases. Additionally, strategic initiatives by key market players, including product launches and partnerships, are expected to further enhance market growth. However, challenges such as stringent regulatory processes, potential adverse effects, and product recalls may pose constraints on the market's expansion.

Market Size of Drug Eluting Stent Industry

Drug Eluting Stent Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.30 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration High

Major Players

Drug Eluting Stent Market Major Players

*Disclaimer: Major Players sorted in no particular order

Drug Eluting Stent Market Analysis

The drug-eluting stent market is expected to register a CAGR of 5.3% during the forecast period.

The COVID-19 pandemic has had a significant impact on the drug-eluting stent market. As countries implemented lockdown measures and healthcare resources were redirected towards managing the pandemic, elective procedures, including cardiac interventions like stent implantation, were postponed or cancelled. For instance, according to an article published by The Lancet, regional health, in May 2022, during the COVID-19 pandemic, the number of patients who underwent percutaneous coronary intervention substantially decreased in Japan. Patients who underwent percutaneous coronary intervention during the pandemic presented high-risk characteristics associated with significantly higher in-hospital mortality. This led to reduced procedures and decreased demand for drug-eluting stents. However, the drug-eluting stent market is witnessing a rebound due to the adoption by healthcare workers and increased awareness of cardiovascular health post-pandemic, thereby driving the market growth in the post-pandemic period.

The primary factor for the growth of the market is the increasing prevalence of cardiovascular diseases such as peripheral and coronary artery diseases as drug-eluting stents are specifically designed to prevent the re-narrowing of blood vessels as these stents are coated with medications that inhibit the proliferation of smooth muscle cells and reduce the risk of restenosis. For instance, according to the American Heart Association 2021 report, peripheral artery disease (PAD) affects more than 200 million people worldwide and is associated with high mortality and morbidity. Thus, an increased burden of peripheral artery diseases contributes to the growth of the studied market.

Additionally, growing demand for minimally invasive surgeries is expected to drive market growth as they involve using small incisions and drug-eluting stents to treat narrowed or blocked coronary arteries. For instance, an article published by the National Library of Medicine in January 2023 reported more than three million minimally invasive surgery cases were calculated annually in the United States. These procedures offer several advantages, such as reduced trauma to the body, shorter hospital stays, faster recovery times, and fewer complications. Hence, with a high demand for minimally invasive procedures, the need for drug-eluting stents increases, leading to market growth.

Furthermore, various strategies adopted by the key market players, such as product launches, mergers and acquisitions, and partnerships to expand the product footprint, are further expected to increase the market growth. For instance, in October 2021, Boston Scientific Corporation reported positive data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.

Hence, as per the factors such as the increasing prevalence of cardiovascular diseases such as peripheral and coronary artery diseases and the growing demand for minimally invasive surgeries, the drug-eluting stent market will likely grow over the forecast period. However, the strict regulatory approval process of products and adverse effects associated with the drug-eluting stents coupled with product recalls are expected to restrain the market's growth.

Drug Eluting Stent Industry Segmentation

As per the scope of the report, a drug-eluting stent (DES) is a medical device used to treat narrowed or blocked coronary arteries, a condition known as coronary artery disease (CAD). It is a stent, implanted into the affected artery to help restore blood flow and support the arterial walls. The Drug-Eluting Stent Market is Segmented by Coating (Polymer Based Coating (Biodegradable and Non-biodegradable), and Polymer Free Coating), Application (Coronary Artery Disease, and Peripheral Artery Disease), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Coating
Polymer Based Coating
Biodegradable
Non-biodegradable
Polymer Free Coating
By Application
Coronary Artery Disease
Peripheral Artery Disease
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Drug Eluting Stent Market Size Summary

The drug-eluting stent market is poised for growth, driven by the increasing prevalence of cardiovascular diseases and the rising demand for minimally invasive surgeries. These stents, designed to prevent the re-narrowing of blood vessels, are gaining traction due to their effectiveness in treating conditions like peripheral and coronary artery diseases. The market experienced a temporary setback during the COVID-19 pandemic as elective procedures were postponed, but it is now rebounding with heightened awareness of cardiovascular health. The demand for minimally invasive surgeries, which offer benefits such as reduced trauma and faster recovery, is further propelling market expansion. Key players in the industry are actively engaging in strategies like product launches and partnerships to enhance their market presence, contributing to the overall growth trajectory of the drug-eluting stent market.

Regionally, North America is expected to maintain a significant share of the drug-eluting stent market, supported by favorable reimbursement policies and a high incidence of artery diseases. The region's well-established healthcare infrastructure and technological advancements in stent systems are key factors driving market growth. The aging population, particularly in countries like the United States, Canada, and Mexico, is also contributing to the increased demand for these stents, as older adults are more susceptible to cardiovascular conditions. Companies in North America are focusing on developing novel products and technologies to stay competitive, further boosting regional market growth. The fragmented nature of the market, with numerous global and regional players, underscores the competitive landscape, with companies like Boston Scientific Corporation, Terumo Corporation, and Abbott Laboratories leading the charge in innovation and market expansion.

Explore More

Drug Eluting Stent Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rise in Geriatric Population and Increasing Prevalence of Cardiovascular Diseases

      2. 1.2.2 Growing Demand for Minimally Invasive Surgeries

    3. 1.3 Market Restraints

      1. 1.3.1 Strict Regulatory Approval Process of Products

      2. 1.3.2 Adverse Effects associated with the Drug Eluting Stents coupled with Product Recalls

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value USD million)

    1. 2.1 By Coating

      1. 2.1.1 Polymer Based Coating

        1. 2.1.1.1 Biodegradable

        2. 2.1.1.2 Non-biodegradable

      2. 2.1.2 Polymer Free Coating

    2. 2.2 By Application

      1. 2.2.1 Coronary Artery Disease

      2. 2.2.2 Peripheral Artery Disease

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Drug Eluting Stent Market Size FAQs

The Global Drug Eluting Stent Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)

Boston Scientific Corporation, Terumo Corporation, Abbott Laboratories, Medtronic Plc and Biotronik SE & Co. KG are the major companies operating in the Global Drug Eluting Stent Market.

Drug Eluting Stent Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)